Quarterly report pursuant to Section 13 or 15(d)

Condensed Combined and Consolidated Balance Sheets (Unaudited)

v3.19.3.a.u2
Condensed Combined and Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2019
Mar. 31, 2019
Current assets:    
Cash $ 123,530 $ 6,985
Prepaid expenses 44 2,632
Income tax receivable   49
Value-added tax receivable 2,996 2,913
Total current assets 126,570 12,579
Property and equipment, net 49 54
Deferred offering costs   1,195
Total assets 126,619 13,828
Current liabilities:    
Accounts payable 2,812 206
Accrued expenses 8,705 6,225
Due to Roivant Sciences Ltd. 3,134 58
Income tax payable 106  
Total liabilities 14,757 6,489
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock value [1]  
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 56,455,376 shares issued and 54,655,376 shares outstanding at December 31, 2019 and 489,066,238 shares authorized, 38,590,381 shares issued and outstanding at March 31, 2019 [1] 5 4
Common stock subscribed [1]   (3)
Additional paid-in capital [1] 182,679 31,830
Accumulated other comprehensive (loss) income [1] (147) 346
Accumulated deficit [1] (70,675) (24,838)
Total stockholders' equity [1] 111,862 7,339
Total liabilities and stockholders' equity [1] 126,619 $ 13,828
Series A Preferred Stock [Member]    
Stockholders' equity:    
Preferred stock value [1]  
[1] Retroactively restated for the reverse recapitalization as described in Note 1.